ASBP
Aspire Biopharma Holdings, Inc. (ASBP) 10Y Growth Potential Analysis (2026)
Overall Score
Growth
Revenue per share remains extremely low at 0.094 and asset turnover is just 0.007, indicating minimal top-line productivity.
No recent news or fresh metrics indicate an improving growth trajectory.
Profitability
TTM margins remain deeply negative, with EBIT margin at -64.7% and net profit margin at -113.1%.
Return on invested capital is still negative at -0.60, showing the business is not generating economic returns on capital.
Financial Health
Liquidity is strong, with a current ratio of 8.0 and cash ratio of 7.2.
The balance sheet shows no debt (debt-to-equity 0) and net current asset value of 11.7M, supporting near-term solvency.
Shareholder Returns
There is no dividend yield and no evidence of sustained shareholder return policy in the fresh data.
Free cash flow remains negative on a per-share basis, limiting capital return capacity.
Valuation
Valuation screens as optically cheap on book value, with price-to-book at 0.79 and price-to-sales at 10.63.
However, negative earnings and cash flow metrics make the valuation difficult to anchor on durable fundamentals.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Aspire Biopharma Holdings, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

